Generated by AI
Rallybio Corp. is a clinical-stage biotechnology company focused on developing and commercializing therapies for severe and rare diseases. The company’s current pipeline centers on areas such as complement dysregulation, hematology, maternal-fetal health, and iron overload disorders. Its lead programs include RLYB116, a complement component 5 inhibitor being developed for diseases driven by complement dysregulation, and RLYB332, a preclinical antibody candidate for iron overload-related conditions. Rallybio also works on therapies for rare maternal-fetal disorders, reflecting its emphasis on areas with significant unmet medical need. Headquartered in New Haven, Connecticut, Rallybio operates as a focused drug development company in the biotechnology sector, advancing specialized treatments designed for patients with serious, underserved conditions.
Website234 Church Street
New Haven, CT, 06510
United States
The latest articles about RLYB.
Summary of Aug 11's posts. Generated by AI.
Summary of Jul 21's posts. Generated by AI.
Summary of Jun 1's posts. Generated by AI.
Summary of Aug 11's posts. Generated by AI.
Investors talking about RLYB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.